IP Library Granted Patent US 7,348,321
Granted Patent B2
US 7,348,321 · App. 10/621,229 · Granted Mar 25, 2008

Flumazenil for the treatment of alcohol dependency

Assignee: Hythiam, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,348,321
App. No.
10/621,229
Granted
Mar 25, 2008
Kind
B2
Abstract

The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.

Claims (11)

1. A method to reduce a desire to drink alcohol in a patient having the desire to drink alcohol comprising administering an effective amount of flumazenil to the patient, wherein the flumazenil is administered sequentially in doses between about 0.1 and 0.3 mg of flumazenil at time intervals between about 1 and 15 minutes, wherein the amount of flumazenil is effective to reduce the desire to drink alcohol in the patient, and the effective amount of flumazenil is between about 1.5 and 2.5 mg/day.

2. The method of claim 1 , wherein the amount of flumazenil that is administered in each sequential administration is about 0.2 mg.

3. The method of claim 1 , wherein the flumazenil is administered at intervals of about 3 minutes.

4. The method of claim 1 , wherein the effective amount of flumazenil is about 2 mg/day.

5. The method of claim 1 , wherein the flumazenil is administered orally or parenterally.

6. The method of claim 5 , wherein the parenteral administration of flumazenil is intravenous administration.

7. The method of claim 1 , wherein the flumazenil is administered at doses of about 0.2 mg of flumazenil at intervals of about 3 minutes until an effective amount of flumazenil has been administered.

8. The method of claim 7 , wherein the effective amount is about 2 mg/day.

9. The method of claim 1 , wherein the flumazenil is administered before, during or after treatment with an additional agent.

10. The method of claim 9 , wherein the additional agent is selected from the group consisting of Vitamin B complex, vitamins, minerals, proteins, amino acids, fluoxetine, and combinations thereof.

11. The method of claim 1 , wherein the flumazenil is administered under sedation.

Assignments (7)
SECURITY INTEREST Recorded Aug 15, 2022
From: ONTRAK, INC.(F.K.A. CATASYS, INC., F.K.A. HYTHIAM, INC.); LD ACQUISITION HOLDINGS, INC.; LIFEDOJO INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 060806/0473 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., AS COLLATERAL AGENT
To: ONTRAK, INC. (FORMERLY KNOWN AS CATASYS, INC.)
Reel/Frame 060672/0554 →
SECURITY INTEREST Recorded Feb 10, 2020
From: HYTHIAM, INC (N/K/A CATASYS, INC.)
To: GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P.
Reel/Frame 051767/0204 →
RELEASE OF SECURITY INTEREST Recorded Oct 24, 2019
From: HIGHBRIDGE MSF INTERNATIONAL LTD F/K/A HIGHBRIDGE INTERNATIONAL LLC
To: CATASYS, INC. F/K/A HYTHIAM, INC.
Reel/Frame 050817/0175 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF THE CONVEYANCE OF THE ASSIGNMENT PREVIOUSLY RECORDED ON REEL 018824 FRAME 0619. ASSIGNOR(S) HEREBY CONFIRMS THE NATURE OF THE CONVEYANCE IS THE GRANTING OF A SECURITY INTEREST RATHER THAN THE TRANSFER OF OWNERSHIP. Recorded Nov 6, 2007
From: HYTHIAM, INC.
To: HIGHBRIDGE INTERNATIONAL LLC, AS AGENT C/O HIGHBRIDGE CAPITAL MANAGEMENT, LLC
Reel/Frame 020075/0814 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2007
From: HYTHIAM, INC.
To: HIGHBRIDGE INTERNATIONAL LLC, AS AGENT C/O HIGHBRIDGE CAPITAL MANAGEMENT, LLC
Reel/Frame 018824/0619 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2004
From: IBANEZ, JUAN JOSE LEGARDA
To: HYTHIAM, INC.
Reel/Frame 015043/0107 →
Continuity (1)
Related Publication 20040092509A1 · May 13, 2004